LifeMD vs Starling Oncology
LFMD and STLN side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LFMD and STLN compare
Starling Oncology is the larger company, worth 5.0 times as much as LifeMD ($428M against $85.8M).
Starling Oncology grew revenue faster over the last twelve months (34.6% versus 3.8% for LifeMD).
LifeMD keeps more of each dollar of sales as profit, with a net margin of 0.12% compared with −5.7% at Starling Oncology.
LifeMD scores higher on the StockData Score (12 against 7 for Starling Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LFMD | STLN |
|---|---|---|
| Size and price | ||
| Market cap | $85.8M | $428M |
| Share price | $1.78 | $4.20 |
| Change, 1 year | −65.3% | 26.9% |
| Change, 5 years | −60.8% | −45.5% |
| Beta (5Y) | 1.71 | 1.72 |
| Employees | 389 | 641 |
| StockData Score | ||
| Total score | 12 (better) | 7 |
| Valuation score | 2 (better) | 1 |
| Growth score | 3 (better) | 2 |
| Performance score | 3 (better) | 2 |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.5× (better) | 0.7× |
| P/B | 10.8× | – |
| P/FCF | – | 22.7× |
| FCF yield | −12.9% | 4.4% (better) |
| Fair value | $2.38 | – |
| Margin of safety | 25.3% | – |
| Growth | ||
| Revenue growth (TTM) | 3.8% | 34.6% (better) |
| Revenue growth, 5Y average | 39.1% (better) | 21.8% |
| Profitability | ||
| Gross margin | 86.1% | – |
| Operating margin | −14.7% | −3.4% (better) |
| Net margin | 0.12% (better) | −5.7% |
| FCF margin | −6.7% | 3.0% (better) |
| Return on equity | 6.5% | – |
| Return on invested capital | – | −96.2% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −2.0× |
| Current ratio | 0.90 | 1.11 (better) |
| Altman Z-score | −3.44 | 1.93 (better) |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Payout ratio | 1545% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 44.9% | 43.4% |
| Held by insiders | 18.2% | 56.6% |
| Insider net buying, 12 months | −$54.1K (better) | −$11.1M |
Go deeper
- LFMD stock overview
- LFMD income statement
- LFMD valuation and score
- STLN stock overview
- STLN income statement
- STLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.